Matthew Pegorie1, David W Denning2, William Welfare3. 1. Public Health England North West Health Protection Team (Greater Manchester), UK. 2. National Aspergillosis Centre, University Hospital of South Manchester, Manchester, UK; The University of Manchester, Manchester, UK; Manchester Academic Health Sciences Centre, University of Manchester, UK. Electronic address: ddenning@manchester.ac.uk. 3. Public Health England North West Health Protection Team (Greater Manchester), UK; Manchester Academic Health Sciences Centre, University of Manchester, UK.
Abstract
BACKGROUND: The burden of fungal disease in the UK is unknown. Only limited data are systematically collected. We have estimated the annual burden of invasive and serious fungal disease. METHODS: We used several estimation approaches. We searched and assessed published estimates of incidence, prevalence or burden of specific conditions in various high risk groups. Studies with adequate internal and external validity allowed extrapolation to estimate current UK burden. For conditions without adequate published estimates, we sought expert advice. RESULTS: The UK population in 2011 was 63,182,000 with 18% aged under 15 and 16% over 65. The following annual burden estimates were calculated: invasive candidiasis 5142; Candida peritonitis complicating chronic ambulatory peritoneal dialysis 88; Pneumocystis pneumonia 207-587 cases, invasive aspergillosis (IA), excluding critical care patients 2901-2912, and IA in critical care patients 387-1345 patients, <100 cryptococcal meningitis cases. We estimated 178,000 (50,000-250,000) allergic bronchopulmonary aspergillosis cases in people with asthma, and 873 adults and 278 children with cystic fibrosis. Chronic pulmonary aspergillosis is estimated to affect 3600 patients, based on burden estimates post tuberculosis and in sarcoidosis. CONCLUSIONS: Uncertainty is intrinsic to most burden estimates due to diagnostic limitations, lack of national surveillance systems, few published studies and methodological limitations. The largest uncertainty surrounds IA in critical care patients. Further research is needed to produce a more robust estimate of total burden.
BACKGROUND: The burden of fungal disease in the UK is unknown. Only limited data are systematically collected. We have estimated the annual burden of invasive and serious fungal disease. METHODS: We used several estimation approaches. We searched and assessed published estimates of incidence, prevalence or burden of specific conditions in various high risk groups. Studies with adequate internal and external validity allowed extrapolation to estimate current UK burden. For conditions without adequate published estimates, we sought expert advice. RESULTS: The UK population in 2011 was 63,182,000 with 18% aged under 15 and 16% over 65. The following annual burden estimates were calculated: invasive candidiasis 5142; Candida peritonitis complicating chronic ambulatory peritoneal dialysis 88; Pneumocystis pneumonia 207-587 cases, invasive aspergillosis (IA), excluding critical care patients 2901-2912, and IA in critical care patients 387-1345 patients, <100 cryptococcal meningitis cases. We estimated 178,000 (50,000-250,000) allergic bronchopulmonary aspergillosis cases in people with asthma, and 873 adults and 278 children with cystic fibrosis. Chronic pulmonary aspergillosis is estimated to affect 3600 patients, based on burden estimates post tuberculosis and in sarcoidosis. CONCLUSIONS: Uncertainty is intrinsic to most burden estimates due to diagnostic limitations, lack of national surveillance systems, few published studies and methodological limitations. The largest uncertainty surrounds IA in critical care patients. Further research is needed to produce a more robust estimate of total burden.
Authors: Laura Loughlin; Thomas P Hellyer; P Lewis White; Danny F McAuley; Andrew Conway Morris; Raquel B Posso; Malcolm D Richardson; David W Denning; A John Simpson; Ronan McMullan Journal: Am J Respir Crit Care Med Date: 2020-10-15 Impact factor: 21.405
Authors: Jan Springer; P Lewis White; Johanna Kessel; Imke Wieters; Daniel Teschner; Daniel Korczynski; Tobias Liebregts; Oliver A Cornely; Stefan Schwartz; Thomas Elgeti; Lisa Meintker; Stefan W Krause; Raquel B Posso; Werner J Heinz; Sandra Fuhrmann; Jörg Janne Vehreschild; Hermann Einsele; Volker Rickerts; Juergen Loeffler Journal: J Clin Microbiol Date: 2018-01-24 Impact factor: 5.948
Authors: M C Almeida; D Antunes; B M A Silva; L Rodrigues; M Mota; O Borges; C Fernandes; T Gonçalves Journal: Mycopathologia Date: 2019-06-11 Impact factor: 2.574
Authors: Jennifer M G Shelton; Roseanna Collins; Christopher B Uzzell; Asmaa Alghamdi; Paul S Dyer; Andrew C Singer; Matthew C Fisher Journal: Appl Environ Microbiol Date: 2022-01-05 Impact factor: 4.792